Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera

Autor: Oguntuyo, Kasopefoluwa, Stevens, Christian S., Hung, Chuan Tien, Ikegame, Satoshi, Acklin, Joshua A., Kowdle, Shreyas S., Carmichael, Jillian C., Chiu, Hsin Ping, Azarm, Kristopher D., Haas, Griffin D., Amanat, Fatima, Klingler, Jéromine, Baine, Ian, Arinsburg, Suzanne, Bandres, Juan C., Siddiquey, Mohammed N. A., Schilke, Robert M., Woolard, Matthew D., Zhang, Hongbo, Duty, Andrew J., Kraus, Thomas A., Moran, Thomas M., Tortorella, Domenico, Lim, Jean K., Gamarnik, Andrea Vanesa, Hioe, Catarina E., Zolla Pazner, Susan, Ivanov, Stanimir S., Kamil, Jeremy, Krammer, Florian, Lee, Benhur, Ojeda, Diego Sebastian, González López Ledesma, María Mora, Costa Navarro, Guadalupe Soledad, Pallarés, H. M., Sanchez, Lautaro Nicolas, Perez, P., Ostrowsk, M., Villordo, S. M., Alvarez, D. E., Caramelo, J. J., Carradori, J., Yanovsky, M. J.

Publikováno v: mBio, Vol 12, Iss 1 (2021)
medRxiv
article-version (status) pre
article-version (number) 1
mBio
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET

The global coronavirus disease 2019 (COVID-19) pandemic has mobilized efforts to develop vaccines and antibody-based therapeutics, including convalescent-phase plasma therapy, that inhibit viral entry by inducing or transferring neutralizing antibodi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b07a5301a1c18870f5cd73a5a8d17ec
https://journals.asm.org/doi/10.1128/mBio.02492-20